High-dose Amycretin Achieves 24% Weight Loss, Outperforming CagriSema and Semaglutide in NMA
Background
The global prevalence of obesity continues to rise, posing significant public health challenges due to its association with numerous cardiometabolic comorbidities. While current incretin-based therapies, such as GLP-1 receptor agonists, have demonstrated efficacy in weight management, there remains a need for even more potent agents to achieve greater weight loss outcomes. Amylin-based therapies (ABTs) represent an emerging class of anti-obesity agents that leverage the satiety-inducing and gastric-emptying-delaying effects of the native amylin hormone, offering a novel mechanism to address the unmet needs in weight management for adults with overweight or obesity without diabetes.
Study Design
Researchers conducted a frequentist random-effects network meta-analysis (NMA) of six randomized controlled trials (N=4642 participants, 12-68 weeks duration) comparing novel amylin-based therapies (ABTs) against placebo or active comparators. The study population included adults with overweight or obesity but without diabetes. Interventions included various doses of subcutaneous amycretin, eloralintide, and CagriSema, alongside established agents like semaglutide 2.4 mg and liraglutide 3.0 mg. The primary outcome measured was the percent change in body weight from baseline, with secondary outcomes including absolute weight changes, anthropometric measures, and gastrointestinal adverse events (GI AEs).
Results
The network meta-analysis revealed that novel amylin-based therapies demonstrated superior weight loss compared to placebo and existing GLP-1RAs. High-dose (HiD) subcutaneous amycretin produced the most substantial reduction in percent body weight. This was followed by HiD eloralintide and HiD CagriSema, all significantly exceeding the efficacy of semaglutide 2.4 mg and liraglutide 3.0 mg. Similar patterns were observed for absolute weight, body mass index, and waist circumference reductions. Gastrointestinal adverse events were more common with HiD ABTs. Nausea, vomiting, and constipation were particularly increased with oral amycretin and CagriSema, while diarrhea primarily increased with semaglutide 2.4 mg. Notably, only HiD CagriSema led to an increase in AE-related discontinuations. These findings, however, are preliminary due to sparse, low-certainty data.
High-dose subcutaneous amycretin produced the largest reduction in percent body weight, with a mean difference of -23.95% (P score 1.00) compared to placebo.
Key Findings
- High-dose subcutaneous amycretin led to the largest percent body weight reduction of -23.95% (P score 1.00) vs. placebo.
- High-dose eloralintide reduced body weight by -18.01% (P score 0.89) vs. placebo.
- High-dose CagriSema reduced body weight by -17.18% (P score 0.85) vs. placebo.
- Semaglutide 2.4 mg achieved -11.45% weight loss, and liraglutide 3.0 mg achieved -6.4%.
- GI AEs (nausea, vomiting, constipation) were more common with HiD ABTs, especially oral amycretin and CagriSema.
Why It Matters
This network meta-analysis suggests that next-generation amylin-based therapies could offer significantly greater weight loss than current GLP-1RAs, potentially redefining obesity treatment paradigms. Individuals seeking advanced weight management options may find these preliminary results compelling, indicating a future where more potent pharmacological interventions are available. While the data is early, the substantial weight loss observed with compounds like high-dose amycretin could lead to new, more effective protocols for managing obesity. However, the increased incidence of GI adverse events, particularly with oral amycretin and CagriSema, highlights the need for careful patient selection and dose titration in future clinical practice. Further large-scale trials are crucial to confirm these findings and establish long-term safety and efficacy.
amycretin
cagrisema
eloralintide
semaglutide
liraglutide
obesity